This quote from your post: We have seen only the clinical data that Missling wanted us to see and as I've posted in multiple times, it is lacking for any further action by the EMA or FDA.
She, Dr. Jun and Dr. Liedkte have seen all the data, warts and all. A273 may just not be that effective for AD. When they take a step back to look at the data from a regulatory viewpoint is there enough to spend 80 million to do a proper P3 (800+ patients, 72 weeks, screen out S1R Q2P variants, place Col24A in the hierarchy). Or is the data so weak when looked at objectively that the A273 program should just be shuttered? Is a pivot to A371 for schizo a better move? Doing both will require a capital raise sooner.
Quote from Interim CEO Kellmeyer today’s PR:
Market Data 
Markets 
